Home » Stocks » INCY

Incyte Corporation (INCY)

Stock Price: $82.62 USD -0.61 (-0.73%)
Updated May 14, 2021 4:00 PM EDT - Market closed
After-hours: $82.65 +0.03 (0.04%) May 14, 7:19 PM
Market Cap 18.17B
Revenue (ttm) 2.70B
Net Income (ttm) 478.48M
Shares Out 219.80M
EPS (ttm) 2.18
PE Ratio 37.88
Forward PE 25.06
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $82.62
Previous Close $83.23
Change ($) -0.61
Change (%) -0.73%
Day's Open 83.75
Day's Range 82.55 - 83.75
Day's Volume 889,201
52-Week Range 75.52 - 110.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PLANEGG, Germany & MUNICH & WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line T...

5 days ago - Business Wire

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal ...

Other stocks mentioned: MOR
5 days ago - Accesswire

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointme...

6 days ago - Business Wire

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.

1 week ago - Zacks Investment Research

Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2 million. Overall product and royalty...

1 week ago - Benzinga

Incyte (INCY) delivered earnings and revenue surprises of 3.08% and -7.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which beat the estimate of $0.64.

1 week ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

1 week ago - Business Wire

Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 week ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SID2021--Incyte Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology Virtual Meeting 2021

1 week ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Present at Upcoming Investor Conference

2 weeks ago - Business Wire

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.

2 weeks ago - Zacks Investment Research

Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream to treat atopic dermatitis (AD). Data prese...

3 weeks ago - Benzinga

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and ...

Other stocks mentioned: LLY
3 weeks ago - PRNewsWire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis

3 weeks ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Incyte Announces New Findings from a Randomized Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

3 weeks ago - Business Wire

Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.

Other stocks mentioned: MOR
3 weeks ago - Zacks Investment Research

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Multiple Abstracts from Incyte's Dermatology Portfolio Accepted for Presentation at the AAD Virtual Meeting Experience

3 weeks ago - Business Wire

INDIANAPOLIS, April 20, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today results from a second Phase 3 trial (BRAVE-AA1) evaluating the efficacy and safet...

Other stocks mentioned: LLY
3 weeks ago - PRNewsWire

WILMINGTON, Del. & PLANEGG, Germany & MUNICH--(BUSINESS WIRE)---- $INCY--First Patient Dosed in P3 inMIND Study Adding Tafasitamab + Lenalidomide to Rituximab in Relapsed or Refractory Follicular or Mar...

3 weeks ago - Business Wire

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first pa...

Other stocks mentioned: MOR
3 weeks ago - Accesswire

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report First Quarter Financial Results.

1 month ago - Business Wire

Eli Lilly And Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) have reported results from the COV-BARRIER Phase 3 study evaluating baricitinib plus standard of care (SoC) versus placebo plus SoC in ...

Other stocks mentioned: LLY
1 month ago - Benzinga

INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus...

Other stocks mentioned: LLY
1 month ago - PRNewsWire

INDIANAPOLIS, April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for...

Other stocks mentioned: LLY
1 month ago - PRNewsWire

The European Commission approves Incyte's (INCY) Pemazyre (pemigatinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

1 month ago - Zacks Investment Research

The European Commission (EC) has approved Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) for the treatment of cholangiocarcinoma, rare cancer that forms in the bile duct. The approval covers...

1 month ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--European Commission Approves Pemazyre (pemigatinib) for Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement

1 month ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Approval of Pemazyre (pemigatinib) in Japan for Unresectable BTC with a FGFR2 Fusion Gene, Worsening After Cancer Chemotherapy

1 month ago - Business Wire

Incyte Corporation NASDAQ: INCY) announced results from the Phase 3 DEVENT study evaluating two doses of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients on mechanical venti...

1 month ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Results of DEVENT Study Evaluating Ruxolitinib (Jakafi) for Patients with COVID-19 Associated ARDS on Mechanical Ventilation

1 month ago - Business Wire

Incyte is betting bigger on ruxolitinib to bring back growth.

2 months ago - The Motley Fool

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR21--Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021.

2 months ago - Business Wire

Eli Lilly and Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announces top-line results from Phase 3 BRAVE-AA2 study evaluating baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA)...

Other stocks mentioned: LLY
2 months ago - Benzinga

INDIANAPOLIS, March 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety...

Other stocks mentioned: LLY
2 months ago - PRNewsWire

If the insiders are buying, other investors should at least pay attention. These seven stocks are ones to keep an eye on here.

Other stocks mentioned: CERN, DD, HSIC, MTD, NUS, SNSE
2 months ago - InvestorPlace

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases this week.

Other stocks mentioned: ADC, CAR, ZTS, AAT, MTEM, OPK, RPRX ...
2 months ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Validation by the EMA of Marketing Authorization Application for Retifanlimab as a Treatment for Squamous Cell Anal Carcinoma (SCAC)

2 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of sNDA for Jakafi (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease

2 months ago - Business Wire

Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream. Ruxolitinib is a selective JAK1/JAK2 inhib...

2 months ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

2 months ago - Business Wire

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the virtual Cowen 41st Annual Health Care Conference on Wednesday, March 3, 2021 at 2:00 p.m. EST. The pre...

3 months ago - Business Wire

With the trading day about halfway over, the broad markets had pulled back slightly on Wednesday.

Other stocks mentioned: JWN, LYFT, TWTR, FCX, GOLD, GT, JACK
3 months ago - 24/7 Wall Street

Several products contributed to the biotech's solid growth.

3 months ago - The Motley Fool

Incyte (INCY) delivered earnings and revenue surprises of 13.41% and 17.87%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 43.08% over the past year to $0.93, which beat the estimate of $0.75.

3 months ago - Benzinga

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

3 months ago - Business Wire

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.

3 months ago - Zacks Investment Research

A handful of names are shrugging off the adverse impact of the pandemic, and have the right stuff to keep on chugging.

Other stocks mentioned: NVDA, SQ
3 months ago - The Motley Fool

Incyte's (INCY) pemigatinib gets positive CHMP opinion by the EMA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion.

3 months ago - Zacks Investment Research

About INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitin... [Read more...]

Industry
Biotechnology
IPO Date
Nov 4, 1993
CEO
Herve Hoppenot
Employees
1,773
Stock Exchange
NASDAQ
Ticker Symbol
INCY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for Incyte stock is "Buy." The 12-month stock price forecast is 105.64, which is an increase of 27.86% from the latest price.

Price Target
$105.64
(27.86% upside)
Analyst Consensus: Buy